

Pfizer COVID-19 Vaccination Schedule

		Months →			
Age & Indication	COVID-19 Vax History ^a	0	1	2	3
Pfizer ^{b, c, d, e} for 6 months - 4 years	Unvaccinated	1st dose	2nd dose ^f (3-8 weeks after 1st)		3rd dose (≥8 weeks after 2nd)
	1 dose of any Pfizer		2nd dose ^f (3-8 weeks after 1st dose)		3rd dose (≥8 weeks after 2nd)
	2 doses of any Pfizer			1 dose (≥8 weeks after last dose)	
	3+ doses of any Pfizer			1 dose (≥8 weeks after last dose)	
Pfizer ^{b, c, e} for ≥5 years	Unvaccinated	1 dose			
	1+ dose(s) of any mRNA vaccine			1 dose (≥8 weeks after last dose)	
	1+ dose(s) Novavax or J&J, including in combination with any mRNA vaccine dose(s)			1 dose (≥8 weeks after last dose)	


- a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).
- b. Bivalent boosters are no longer authorized for this age group. Updated (2023-2024 Formula) COVID-19 vaccines are now available.
- c. Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic)
- d. Children ages 6 months-4 years who are unvaccinated or have begun the vaccine series are recommended to receive homologous (i.e., from the same manufacturer) updated (2023-2024 Formula) mRNA vaccine doses, dependent on vaccine manufacturer.
- e. For people who are moderately or severely immunocompromised: Please see schedule below.
- f. An 8-week interval between the first and second doses of Moderna and Pfizer COVID-19 vaccines might be optimal for some people ages 6 months-64 years, especially for males ages 12-39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

Moderna COVID-19 Vaccination Schedule

		Months →			
Age & Indication	COVID-19 Vax History ^a	0	1	2	3
Moderna ^{b, c, d, e} for 6 months - 4 years	Unvaccinated	1st dose	2nd dose ^f (4-8 weeks after 1st)		
	1 dose of any Moderna		1 dose ^f (4-8 weeks after last dose)		
	2+ doses of any Moderna			1 dose (≥8 weeks after last dose)	
Moderna ^{b, c, e} for ≥5 years	Unvaccinated	1 dose			
	1+ dose(s) of any mRNA vaccine			1 dose (≥8 weeks after last dose)	
	1+ dose(s) Novavax or J&J, including in combination with any mRNA vaccine dose(s)			1 dose (≥8 weeks after last dose)	

- a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).
- b. Bivalent boosters are no longer authorized for this age group. Updated (2023-2024 Formula) COVID-19 vaccines are now available.
- c. Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic)
- d. Children ages 6 months-4 years who are unvaccinated or have begun the vaccine series are recommended to receive homologous (i.e., from the same manufacturer) updated (2023-2024 Formula) mRNA vaccine doses, dependent on vaccine manufacturer.
- e. For people who are moderately or severely immunocompromised: Please see schedule below.
- f. An 8-week interval between the first and second doses of Moderna and Pfizer COVID-19 vaccines might be optimal for some people ages 6 months-64 years, especially for males ages 12-39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

Novavax COVID-19 Vaccination Schedule



a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).

b. Bivalent boosters are no longer authorized for this age group. Updated (2023–2024 Formula) COVID-19 vaccines are now available.

c. Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic)

d. **For people who are moderately or severely immunocompromised:** Please see schedule below.

e. The primary series doses are separated by 3–8 weeks. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine.

Want more information on COVID-19 vaccine schedules?

CDC Interim Clinical Considerations

SCAN ME



<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

NDHHS COVID-19 Vaccine Information

SCAN ME



<https://www.hhs.nd.gov/health/coronavirus/vaccine-information>

Access the digital copy of this handout

SCAN ME



https://www.ndsu.edu/centers/immunize/covid_19/

COVID-19 Vaccination Schedules for People Who are Moderately or Severely Immunocompromised

Pfizer COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised

		Months →			
Age & Indication	COVID-19 Vax History ^a	0	1	2	3
Pfizer ^{b, c, d} for 6 months - 4 years	Unvaccinated	1st dose	2nd dose (3 weeks after 1st)		3rd dose (≥8 weeks after 2nd)
	1 dose of any Pfizer		2nd dose (3 weeks after last dose)		3rd dose (≥8 weeks after 2nd)
	2 doses of any Pfizer			1 dose (≥8 weeks after last dose)	
	3+ doses of any Pfizer			1 dose (≥8 weeks after last dose)	
Pfizer ^{b, c} for ≥5 years	Unvaccinated	1st dose	2nd dose (3 weeks after 1st)		3rd dose (≥4 weeks after 2nd)
	1 dose of any Pfizer		2nd dose (3 weeks after last dose)		3rd dose (≥4 weeks after 2nd)
	2 doses of any Pfizer			1 dose (≥4 weeks after last dose)	
	3+ doses of any mRNA vaccine			1 dose (≥8 weeks after last dose)	
	1+ dose(s) of Novavax or J&J, including in combination with any mRNA vaccine dose(s)			1 dose (≥8 weeks after last dose)	

a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).

b. For people who are moderately or severely immunocompromised: Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last updated (2023-2024 Formula) mRNA vaccine dose.

c. Bivalent boosters are no longer authorized for this age group. Updated (2023-2024 Formula) COVID-19 vaccines are now available.

d. Children ages 6 months-4 years who are unvaccinated or have begun the vaccine series are recommended to receive homologous (i.e., from the same manufacturer) updated (2023-2024 Formula) mRNA vaccine doses, dependent on vaccine manufacturer.

Moderna COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised

		Months →			
Age & Indication	COVID-19 Vax History ^a	0	1	2	3
Moderna ^{b, c, d} for 6 months and older	Unvaccinated	1st dose	2nd dose (4 weeks after 1st dose)		3rd dose (≥4 weeks after 2nd dose)
	1 dose of any Moderna		2nd dose (4 weeks after last dose)		3rd dose (≥4 weeks after 2nd dose)
	2 doses of any Moderna			1 dose (≥4 weeks after last dose)	
	3+ doses of any mRNA vaccine			1 dose (≥8 weeks after last dose)	
	1 or more doses of Novavax or J&J, including in combination with any mRNA vaccine dose(s)			1 dose (≥8 weeks after last dose)	

a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).

b. For people who are moderately or severely immunocompromised: Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last updated (2023-2024 Formula) mRNA vaccine dose.

c. Bivalent boosters are no longer authorized for this age group. Updated (2023-2024 Formula) COVID-19 vaccines are now available.

d. Children ages 6 months-4 years who are unvaccinated or have begun the vaccine series are recommended to receive homologous (i.e., from the same manufacturer) updated (2023-2024 Formula) mRNA vaccine doses, dependent on vaccine manufacturer.

Novavax COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised


		Months →			
Age & Indication	COVID-19 Vax History ^a	0	1	2	3
Novavax ^{b, c} ≥12 years	Unvaccinated	1st dose	2nd dose (3 weeks after 1st dose)		
	3+ doses of any mRNA vaccine			1 dose (≥8 weeks after last dose)	
	1+ doses of any mRNA; 1+ doses of Novavax or J&J - including in combination with any original monovalent/bivalent COVID vaccine doses			1 dose (≥8 weeks after last dose)	

a. COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Novavax COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s); and for people ages 18 years and older, Janssen (J&J) COVID-19 Vaccine dose(s), alone or in combination with any mRNA vaccine dose(s).

b. Bivalent boosters are no longer authorized for this age group. Updated (2023–2024 Formula) COVID-19 vaccines are now available.

c. For people who are moderately or severely immunocompromised: Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last updated (2023–2024 Formula) vaccine dose.

COVID-19 Risk Continuum



The most important risk factor is increasing age.

Sociodemographic factors and non-pharmaceutical interventions affect exposure risk

This figure outlines several considerations that impact risk for COVID-19, which exists on a continuum and is highly individualized. Listed comorbidities and immunosuppressive conditions are illustrative, not exhaustive; there is significant variability in the net state of immunocompromise even among people with the same condition.

Figure adapted from a graphic created by the Infectious Diseases Society of America.